Cargando…
GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson’s disease via its RGS homology domain
Degeneration of dopaminergic neurons causes Parkinson’s disease. Dopamine replacement therapy with L-DOPA is the best available treatment. However, patients develop L-DOPA-induced dyskinesia (LID). In the hemiparkinsonian rat, chronic L-DOPA increases rotations and abnormal involuntary movements mod...
Autores principales: | Ahmed, Mohamed R., Bychkov, Evgeny, Li, Lingyong, Gurevich, Vsevolod V., Gurevich, Eugenia V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455246/ https://www.ncbi.nlm.nih.gov/pubmed/26043205 http://dx.doi.org/10.1038/srep10920 |
Ejemplares similares
-
The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment
por: Managò, Francesca, et al.
Publicado: (2012) -
G Protein-Coupled Receptor Kinase 2 (GRK2) and 5 (GRK5)
Exhibit Selective Phosphorylation of the Neurotensin Receptor in Vitro
por: Inagaki, Sayaka, et al.
Publicado: (2015) -
Arrestins: ubiquitous regulators of cellular signaling pathways
por: Gurevich, Eugenia V, et al.
Publicado: (2006) -
Molecular Mechanisms of GPCR Signaling: A Structural Perspective
por: Gurevich, Vsevolod V., et al.
Publicado: (2017) -
Arrestin-mediated signaling: Is there a controversy?
por: Gurevich, Vsevolod V, et al.
Publicado: (2018)